Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential
Open accessAbstract
The major challenges in the delivery and therapeutic efficacy of nano-delivery systems in chronic obstructive airway conditions are airway defense, severe inflammation and mucous hypersecretion. Chronic airway inflammation and mucous hypersecretion are hallmarks of chronic obstructive airway diseases, including asthma, COPD (chronic obstructive pulmonary disease) and CF (cystic fibrosis). Distinct etiologies drive inflammation and mucous hypersecretion in these diseases, which are further induced by infection or components of cigarette smoke. Controlling chronic inflammation is at the root of treatments such as corticosteroids, antibiotics or other available drugs, which pose the challenge of sustained delivery of drugs to target cells or tissues. In spite of the wide application of nano-based drug delivery systems, very few are tested to date. Targeted nanoparticle-mediated sustained drug delivery is required to control inflammatory cell chemotaxis, fibrosis, protease-mediated chronic emphysema and/or chronic lung obstruction in COPD. Moreover, targeted epithelial delivery is indispensable for correcting the underlying defects in CF and targeted inflammatory cell delivery for controlling other chronic inflammatory lung diseases. We propose that the design and development of nano-based targeted theranostic vehicles with therapeutic, imaging and airway-defense penetrating capability, will be invaluable for treating chronic obstructive lung diseases. This paper discusses a novel nano-theranostic strategy that we are currently evaluating to treat the underlying cause of CF and COPD lung disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PLGA and PEG polymeric vesicle has been suggested for delivery of COPD drugs prednisolone and theophylline.
“In this scenario, a potential multifunctional polymeric vesicle composed of PLGA and PEG has been suggested for the delivery of COPD drugs such as prednisolone (corticosteroid) and theophylline (bronchiodilator).185”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [185]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Biodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V. S., Torchilin, V. P., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,924 · see citing works
Multifunctional Inorganic Nanoparticles for Imaging, Targeting, and Drug Delivery
Liong, M., Lu, J., Kovochich, M., Xia, T., Ruehm, S. G., Nel, A. E., Tamanoi, F., & Zink, J. I. (2008) · ACS Nano · doi:10.1021/nn800072t · Cited by 1,932 · see citing works
Chronic obstructive pulmonary disease: molecular and cellularmechanisms
Barnes, P. J., Shapiro, S. D., & Pauwels, R. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00040703 · Cited by 1,440 · see citing works
Sahoo, S. K., Panyam, J., Prabha, S., & Labhasetwar, V. D. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00127-x · Cited by 992 · see citing works
The cytokine network in asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36130 · Cited by 982 · see citing works
Mediators of Chronic Obstructive Pulmonary Disease
Barnes, P. J. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.2 · Cited by 710 · see citing works
Inhaled nanoparticles—A current review
Yang, W. P., Peters, J. I., & Williams, R. O. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.02.011 · Cited by 670 · see citing works
Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction
Chung, K. F., & Adcock, I. M. (2008) · European Respiratory Journal · doi:10.1183/09031936.00018908 · Cited by 599 · see citing works
FDG PET of Infection and Inflammation
Love, C., Tomas, M. B., Tronco, G. G., & Palestro, C. J. (2005) · Radiographics · doi:10.1148/rg.255045122 · Cited by 484 · see citing works
Biomédical applications of nanotechnology — implications for drug targeting and gene therapy
Davis, S. S. (1997) · Trends in biotechnology · doi:10.1016/s0167-7799(97)01036-6 · Cited by 417 · see citing works
Zhang, W., Yang, H., Kong, X., Mohapatra, S., San-Juan-Vergara, H. G., Hellermann, G., Behera, S., Singam, R., Lockey, R. F., & Mohapatra, S. S. (2004) · Nature Medicine · doi:10.1038/nm1174 · Cited by 364 · see citing works
Role of HDAC2 in the Pathophysiology of COPD
Barnes, P. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163257 · Cited by 322 · see citing works
The genesis of cystic fibrosis lung disease
Wine, J. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6222 · Cited by 275 · see citing works
Weng, K. C., Noble, C. O., Papahadjopoulos‐Sternberg, B., Chen, F. F., Drummond, D. C., Kirpotin, D. B., Wang, D., Hom, Y. K., Hann, B. C., & Park, J. W. (2008) · Nano Letters · doi:10.1021/nl801488u · Cited by 274 · see citing works
Leevy, W. M., Gammon, S. T., Jiang, H., Johnson, J. R., Maxwell, D. J., Jackson, E. N., Márquez, M., Piwnica-Worms, D. R., & Smith, B. D. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0665592 · Cited by 257 · see citing works
Fang, J. Q., Sawa, T., & Maeda, H. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47932-x_2 · Cited by 221 · see citing works
Verbavatz, J., Ma, T., Gobin, R., & Verkman, A. S. (1997) · Journal of Cell Science · doi:10.1242/jcs.110.22.2855 · Cited by 221 · see citing works
Culpitt, S. V., de Matos, C., Russell, R. E. K., Donnelly, L., Rogers, D. F., & Barnes, P. J. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2105106 · Cited by 180 · see citing works
Nanodelivery in airway diseases: Challenges and therapeutic applications
Roy, I., & Vij, N. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.07.001 · Cited by 137 · see citing works
Self-citationVij, N., Min, T., Marasigan, R. E. R., Belcher, C. N., Mazur, S., Ding, H. Y., Yong, K., & Roy, I. (2010) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-8-22 · Cited by 126 · see citing works
Self-citationMicro- and nanocarrier-mediated lung targeting
Kurmi, B. D., Kayat, J., Gajbhiye, V., Tekade, R. K., & Jain, N. K. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.492212 · Cited by 122 · see citing works
Guest editorial: The conception of FDG-PET imaging
Alavi, A. A., & Reivich, M. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.29269 · Cited by 120 · see citing works
Alveolar inflammation in cystic fibrosis
Ulrich, M., Worlitzsch, D., Viglio, S., Siegmann, N., Iadarola, P., Shute, J. K., Geiser, M., Pier, G. B., Friedel, G., Barr, M. L., et al. (2010) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2010.03.001 · Cited by 117 · see citing works
Barnes, P. J. (2006) · Thorax · doi:10.1136/thx.2006.061002 · Cited by 88 · see citing works
Aspects on pathophysiological mechanisms in COPD
Larsson, K. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01837.x · Cited by 80 · see citing works
Chen, D. L., Rosenbluth, D., Mintun, M. A., & Schuster, D. P. (2006) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01429.2005 · Cited by 80 · see citing works
Quantum dot probes for bacteria distinguish Escherichia coli mutants and permit in vivo imaging
Leevy, W. M., Lambert, T. N., Johnson, J. R., Morris, J. D., & Smith, B. D. (2008) · Chemical Communications · doi:10.1039/b803590c · Cited by 61 · see citing works
FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma
Kuo, P. H., McClennan, B. L., Carlson, K. R., Wilson, L. D., Edelson, R. L., HEALD, P. W., & Girardi, M. (2008) · Molecular Imaging and Biology · doi:10.1007/s11307-007-0127-y · Cited by 55 · see citing works
Hirano, T., Yamagata, T., Gohda, M., Yamagata, Y., Ichikawa, T., Yanagisawa, S., Ueshima, K., Akamatsu, K., Nakanishi, M., Matsunaga, K., et al. (2006) · Thorax · doi:10.1136/thx.200x.058156 · Cited by 52 · see citing works
FDG-PET for imaging of non-osseous infection and inflammation.
Vos, F. J., Bleeker‐Rovers, C. P., Corstens, F. H. M., Kullberg, B. J., & Oyen, W. J. G. (2006) · PubMed · Cited by 44 · see citing works
Kuo, P. H., Carlson, K. R., Christensen, I. R., Girardi, M., & HEALD, P. W. (2008) · Molecular Imaging and Biology · doi:10.1007/s11307-008-0161-4 · Cited by 26 · see citing works
KRAMER, E. L. (1996) · Lung Cancer · doi:10.1016/0169-5002(96)87797-x · Cited by 24 · see citing works
Use of Theophylline in the Treatment of COPD
Ramsdell, J. (1995) · CHEST Journal · doi:10.1378/chest.107.5_supplement.206s · Cited by 16 · see citing works
Wu, Y., Kotzer, C. J., Makrogiannis, S. K., Logan, G. A., Haley, H., Barnette, M. S., & Sarkar, S. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0423-9 · Cited by 14 · see citing works
[Autoradiographic demonstration of 18F-FDG distribution within mouse FM3A tumor tissue in vivo].
Kubota, R., Yamada, S., Kubota, K., Ishiwata, K., TAMAHASHI, N., & Ido, T. (1992) · PubMed · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645 · see citing works
Emerging trends in macromolecular antimicrobials to fight multi-drug-resistant infections
Engler, A. C., Wiradharma, N., Ong, Z. Y., Coady, D. J., Hedrick, J. L., & Yang, Y. Y. (2012) · Nano Today · doi:10.1016/j.nantod.2012.04.003 · Cited by 357 · see citing works
Electrospun nanofibres in drug delivery: advances in controlled release strategies
Gaydhane, M. K., Sharma, C. S., & Majumdar, S. (2023) · RSC Advances · doi:10.1039/d2ra06023j · Cited by 182 · see citing works
Polymeric multifunctional nanomaterials for theranostics
Peng, H., Liu, X., Wang, G., Li, M., Bratlie, K. M., Cochran, E. W., & Wang, Q. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00617a · Cited by 157 · see citing works
Forest, V., & Pourchez, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114173 · Cited by 131 · see citing works
Nanotechnology based therapeutics for lung disease
Doroudian, M., MacLoughlin, R. J., Poynton, F. E., Prina‐Mello, A., & Donnelly, S. C. (2019) · Thorax · doi:10.1136/thoraxjnl-2019-213037 · Cited by 127 · see citing works
Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine
Cojocaru, E., Petriș, O. R., & Cojocaru, C. (2024) · Pharmaceuticals · doi:10.3390/ph17081059 · Cited by 123 · see citing works
Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases
Li, C., Li, L., Chen, S., Zhang, J., & Lü, W.-L. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00200 · Cited by 121 · see citing works
Recent applications and strategies in nanotechnology for lung diseases
Zhong, W., Zhang, X., Zeng, Y., Lin, D., & Wu, J. (2021) · Nano Research · doi:10.1007/s12274-020-3180-3 · Cited by 115 · see citing works
Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases
Vij, N., Min, T., Bodas, M., Gorde, A., & Roy, I. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.06.008 · Cited by 85 · see citing works
Self-citationCazzola, M., Cavalli, F., Usmani, O. S., & Rogliani, P. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1739021 · Cited by 76 · see citing works
Nanotherapeutics for pulmonary drug delivery: An emerging approach to overcome respiratory diseases
Kole, E. B., Jadhav, K., Shirsath, N. R., Dudhe, P. B., Verma, R. K., Chatterjee, A., & Naik, J. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104261 · Cited by 73 · see citing works
New perspectives in nanotherapeutics for chronic respiratory diseases
da Silva, A. L., Cruz, F. F., Rocco, P. R. M., & Morales, M. M. (2017) · Biophysical Reviews · doi:10.1007/s12551-017-0319-x · Cited by 72 · see citing works
Passi, M., Shahid, S., Chockalingam, S., Sundar, I. K., & Packirisamy, G. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s242516 · Cited by 65 · see citing works
Alhajj, N., Zakaria, Z., Naharudin, I., Ahsan, F., Li, W., & Wong, T. W. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.02.001 · Cited by 59 · see citing works
Shahriari, M., Sedigh, M. A., Shahriari, M., Stenzel, M. H., Zangeneh, M. M., Zangeneh, A., Mahdavi, B., Asadnia, M., Gholami, J., Karmakar, B., et al. (2022) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2022.109523 · Cited by 56 · see citing works
Howell, M., Wang, C., Mahmoud, A., Hellermann, G., Mohapatra, S. S., & Mohapatra, S. S. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0132-4 · Cited by 46 · see citing works
Current views in chronic obstructive pulmonary disease pathogenesis and management
Alfahad, A. J., Alzaydi, M. M., Aldossary, A. M., Alshehri, A. A., Almughem, F. A., Zaidan, N. M., & Tawfik, E. A. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.10.008 · Cited by 46 · see citing works
Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease
Bodas, M., & Vij, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00020 · Cited by 34 · see citing works
Self-citationNovel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models
Baker, K. E., Bonvini, S. J., Donovan, C., Foong, R. E., Han, B., Jha, A., Shaifta, Y., Smit, M., Johnson, J. R., & Moir, L. M. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2014.05.008 · Cited by 33 · see citing works
Brockman, S. M., Bodas, M., Silverberg, D., Sharma, A. K., & Vij, N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184793 · Cited by 29 · see citing works
Self-citationNano-based rescue of dysfunctional autophagy in chronic obstructive lung diseases
Vij, N. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1223040 · Cited by 27 · see citing works
Self-citationNanoparticle-Based Drug Delivery for Chronic Obstructive Pulmonary Disorder and Asthma
Wadhwa, R., Aggarwal, T., Thapliyal, N., Chellappan, D. K., Gupta, G., Gulati, M., Collet, T., Oliver, B. G. G., Williams, K. A., Hansbro, P. M., et al. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818823-1.00005-3 · Cited by 25 · see citing works
S100A12 and the Airway Smooth Muscle: Beyond Inflammation and Constriction
Camoretti-Mercado, B., & Karrar, E. E. (2012) · Journal of Allergy & Therapy · doi:10.4172/2155-6121.s1-007 · Cited by 22 · see citing works
Kokkinis, S., Singh, M., Paudel, K. R., Rubis, G. D., Saeid, A. B., Jessamine, V., Datsyuk, J. K., Singh, S. K., Vishwas, S., Adams, J., et al. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.103761 · Cited by 15 · see citing works
Sweef, O., Mahfouz, R. Z., Taşcıoğlu, T., Albowaidey, A. A., Abdelmonem, M. A., Asfar, M., Zaabout, E., Corcino, Y. L., Thomas, V. D., Choi, E. S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169001 · Cited by 15 · see citing works
Sherkawi, T. E., Saeid, A. B., Yeung, S., Chellappan, D. K., Mohamad, M. S. B., Kokkinis, S., Sudhakar, S., Singh, S. K., Gupta, G., Paudel, K. R., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155629 · Cited by 14 · see citing works
Faraj, J., Bodas, M., Pehote, G., Swanson, D., Sharma, A., & Vij, N. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1575807 · Cited by 14 · see citing works
Self-citationAssessing carbon‐encapsulated iron nanoparticles cytotoxicity in Lewis lung carcinoma cells
Grudziński, I. P., Bystrzejewski, M., Cywińska, M. A., Kośmider, A., Popławska, M., Cieszanowski, A., Fijałek, Z., Ostrowska, A., & Parzonko, A. (2013) · Journal of Applied Toxicology · doi:10.1002/jat.2947 · Cited by 13 · see citing works
Vij, N. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-953-2_24 · Cited by 11 · see citing works
Self-citationCywińska, M. A., Bystrzejewski, M., Popławska, M., Kośmider, A., Zdanowski, R., Lewicki, S., Fijałek, Z., Ostrowska, A., Bamburowicz‐Klimkowska, M., Cieszanowski, A., et al. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.04.011 · Cited by 8 · see citing works
Vij, N. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0319-2_11 · Cited by 7 · see citing works
Self-citationVij, N. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020096 · Cited by 6 · see citing works
Self-citationTargeting Multiple Pathophysiological Axes in COPD: Nanomaterial Advances
Zhang, Q., Xu, S., Yang, C., Wang, X., Liu, T., Zhang, X., Qu, C., Wu, J. ‐., Yang, J., & Xing, X. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s542725 · Cited by 5 · see citing works
Nanomedicines: Impactful Approaches for Targeting Pulmonary Diseases
Dhoundiyal, S., Alam, A., Kaur, A., & Sharma, S. (2023) · Pharmaceutical Nanotechnology · doi:10.2174/2211738511666230525151106 · Cited by 5 · see citing works
Price, P. S., & Leonard, J. A. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.05.007 · Cited by 5 · see citing works
Precision nanoparticles for prognosis-based early intervention of COPD-emphysema
Vij, N. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2355997 · Cited by 5 · see citing works
Self-citationMaurya, S., Srivastava, R., Arfin, S., Hawthorne, S. J., Jha, N. K., Agrawal, K., Raj, S., Rathi, B., Kumar, A. J., Raj, R., et al. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0437 · Cited by 4 · see citing works
Zhou, H., Gunsten, S. P., Zhegalova, N. G., Bloch, S. R., Achilefu, S. A., Holley, J. C., Schweppe, D., Akers, W. J., Brody, S. L., Eades, W. C., et al. (2015) · Cytometry Part A · doi:10.1002/cyto.a.22658 · Cited by 4 · see citing works
Strategies for Enhanced Drug Targeting to Inflamed Lungs: Novel Perspectives
Pardeshi, C. V., Pardeshi, S. R., & Naik, J. (2022) · Springer eBooks · doi:10.1007/978-981-16-4392-7_12 · Cited by 4 · see citing works
Hussain, Y., Cui, J., Khan, H. Z., Makvandi, P., & Alam, W. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.25 · Cited by 3 · see citing works
Han, B., Pan, Y., & Li, H. (2023) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2023.3532 · Cited by 2 · see citing works
Theranostic drug delivery systems for targeted therapy of lung diseases
Katas, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820658-4.00019-4 · Cited by 2 · see citing works
Exploring the state-of-art of lipid nanomedicines for obstructive pulmonary diseases
Sharma, H., Kaushik, M., Ashique, S., Islam, A., Mandal, S., & Mojgani, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22374-7.00010-4 · Cited by 1 · see citing works
Nano-Micro Polymeric Structures with Antimicrobial Activity in Solution
Rodríguez‐Hernández, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-47961-3_4 · Cited by 1 · see citing works
Nanoparticle Formulations and Delivery Strategies for Sustained Drug Release in the Lungs
Cuestas, M. L., Devoto, T. B., Toscanini, M. A., Limeres, M. J., Islan, G. A., & Castro, G. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821185-4.00002-6 · Cited by 1 · see citing works
Theranostic Applications of Nanotechnology in Chronic Obstructive Lung Diseases
Gorde, A. (2012) · Pan Stanford Publishing eBooks · doi:10.1201/b12778-2 · Cited by 1 · see citing works
Utility of nanomedicine and nanocarriers for noninfectious disease treatment
Tuteja, J., Vyas, A., & Sand, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95325-2.00014-6 · Cited by 1 · see citing works
Current challenges and future scope of nanoparticles in chronic obstructive pulmonary disease
Pandey, S., Garg, R., Kant, S., Verma, A., Gaur, P., & Agarwal, M. (2021) · Eurasian Journal of Pulmonology · doi:10.4103/ejop.ejop_57_19
Jain, K. K. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-983-9_11
Jain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6966-1_11
Nanoparticles in Chronic Respiratory Diseases
Raja, A., Mahendiratta, S., Singh, H., Shekhar, N., Prakash, A., & Medhi, B. (2022) · Springer eBooks · doi:10.1007/978-981-16-4392-7_8
Nanomedicine Applied to Inflammatory and Infectious Pulmonary Diseases
Kaur, A., Sharma, R., Sundar, I. K., & Packirisamy, G. (2023) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-19-8342-9_11
Nanosystems - Combination products
Sapa, H., & Kamalasanan, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22257-3.00007-6
Carbon nanotubes for the management of chronic obstructive pulmonary disease
Sarath Chandran, C., Rahul, K., Sajayan, K., Shaji, A. K., Gopika Nath, C., Hiba Asrar, K., Muhammed, H., & Nair, R. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43946-9.00015-x
Theranostic nanoparticles for the management of COPD
Kaur, J., Kaur, H., & Sapra, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43946-9.00014-8
Nadi, A., Malekzadeh, R., Karimzadeh, F., Fard, E. S., Hosseini, M., & Mirzaei, S. A. (2026) · Polymers for Advanced Technologies · doi:10.1002/pat.70591
Jafari, A., Manzari‐Tavakoli, A., Tavakoli, M. M., Hashemian, S. M., Jamaati, H., Akhtari, M., Tabarsi, P., & Omrani, M. (2026) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2026.2714060
- Authors
- Vij, N.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Vij, Neeraj
- ORCID
- Vij, Neeraj
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2011-06-28
- Volume
- 8
- Issue
- 9
- Pages
- 1105-1109
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- PMC
- PMC3159857
- OpenAlex
- W2044012073
- Cited by
- 60
- References
- 36
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 6 · 2019: 7 · 2017: 3 · 2016: 4 · 2015: 2 · 2014: 1 · 2013: 2 · 2012: 6
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Expert Opinion on Drug Delivery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Public Health Service (RHL-096931)
- National Heart, Lung, and Blood Institute (R03HL096931)
- National Center for Research Resources (UL1RR025005, RR025005)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- chronic obstructive pulmonary disease, cystic fibrosis, asthma, airway inflammation, mucus hypersecretion, targeted drug delivery, nanoparticle drug delivery, emphysema, pulmonary fibrosis, airway defense
- MeSH terms
- Animals, Anti-Inflammatory Agents, Cystic Fibrosis, Humans, Drug Delivery Systems, Pulmonary Disease, Chronic Obstructive, Nanotechnology, Nanoparticles, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
